Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors
Wednesday, May 07, 2025IDEAYA Biosciences Inc a precision medicine oncology company committed to the discovery and development of targeted therapeutics announced the clearance of an investigational new drug IND application with the US Food and Drug Administration
Calquence plus chemoimmunotherapy approved in the EU as first and only BTK inhibitor for 1st-line mantle cell lymphoma
Tuesday, May 06, 2025AstraZenecas Calquence acalabrutinib in combination with bendamustine and rituximab has been approved in the European Union EU for the treatment of adult patients with previously untreated mantle cell lymphoma MCL
BioLife Plasma Services Introduces the New Fresenius Kabi Adaptive Nomogram Across its U.S. Network of Plasma Donation Centers
Monday, May 05, 2025BioLife Plasma Services part of Takeda today announced that it has begun introducing the new Fresenius Kabi Adaptive Nomogram across its US network of plasma donation centers
Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas
Friday, May 02, 2025Biosplice Therapeutics Inc Biosplice a clinicalstage biotechnology company pioneering advancements in small molecule inhibition of CDClike kinases CLK and Dualspecificity tyrosine phosphorylationregulated DYRK kinases
Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia
Thursday, May 01, 2025Nxera Pharma Co Ltd today announces that its partner Neurocrine Biosciences Inc Neurocrine has initiated a Phase registrational program to evaluate the efficacy safety and tolerability of NBI NBI an investigational
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Thursday, May 01, 2025Dimerix Limited and Amicus Therapeutics Nasdaq FOLD Amicus today announced that the two companies have entered into an exclusive license agreement for the commercialization of Dimerix Phase drug candidate DMX for all indications
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
Wednesday, April 30, 2025Moleculin Biotech Inca latestage pharmaceutical company with a broad portfolio of drug candidates targeting hardtotreat cancers and viral infections today announced that an abstract and poster presentation regarding the Companys
FYR Enters Know-How Agreement with Mayo Clinic to Collaborate on Blood-Based Biomarker Solutions for Parkinson’s Disease
Wednesday, April 30, 2025FYR a biotechnology company leveraging extracellular vesicles EVs to dynamically observe disease and treatment responses today announced a collaboration with Mayo Clinic seeking to advance the use of bloodbased biomarkers
New members in Eppendorf's epMotion® family – 4-channel dispensing tools
Tuesday, April 29, 2025Eppendorf is expanding its product range in the field of automated liquid handling with the introduction of three new epMotion channel dispensing tools which have been specially developed for the automation of liquid handling processes in tubes These...
Prilenia enters into a collaboration and licensing agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and certain other markets
Tuesday, April 29, 2025Prilenia Therapeutics BV a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntingtons disease HD and amyotrophic lateral sclerosis ALS
